![]() ![]() ![]() No other potential conflicts of interest were reported.Legal technologies wait for no one, including you. Research Funding: Novartis, AstraZeneca, Taiho Pharmaceutical, Genentech, Calithera Biosciences, Debiopharm Group, Bayer HealthCare Pharmaceuticals, Aileron Therapeutics, Puma Biotechnology, CytomX Therapeutics, Jounce Therapeutics, Zymeworks, Curis, Pfizer, eFFECTOR Therapeutics, AbbVie, Boehringer Ingelheim (I), Guardant Health (Inst), Daiichi Sankyo, GlaxoSmithKline Travel, Accommodations, Expenses: Roche, Boehringer Ingelheim Funda Meric-BernstamĬonsulting or Advisory Role: Genentech, Inflection Biosciences, Pieris Pharmaceuticals, Clearlight Diagnostics, Darwin Health, Samsung Bioepis, Spectrum Pharmaceuticals, Aduro Biotech, Origimed, Xencor, Debiopharm Group, Mersana Research Funding: Novartis (I), AstraZeneca (I), Taiho Pharmaceutical (I), Debiopharm Group (I), Bayer HealthCare Pharmaceuticals (I), Alleron Therapeutics (I), Puma Biotechnology (I), Verastem (I), CytomX Therapeutics (I), Jounce Therapeutics (I), Zymeworks (I), Effective Pharmaceuticals (I), Curis (I), Boehringer Ingelheim Honoraria: Genentech (I), Sysmex (I), RocheĬonsulting or Advisory Role: Genentech/Roche (I), Novartis (I) Stock and Other Ownership Interests: McKesson, Mylan Yekaterina KhotskayaĮmployment: Molecular Health Nora SánchezĮmployment: Foundation Medicine Elmer V. Several OCTANE components are publically available and may be useful to other precision oncology programs. OCTANE is a general informatics framework that can be helpful for establishing and maintaining a comprehensive database necessary for automating patient-trial matching, which facilitates the successful delivery of personalized cancer care on a routine basis. We compared the update module with expert review, and the module achieved 98.5% accuracy, 0% false-negative rate, and 2.3% false-positive rate. To date, we have used the database to screen 4,220 patients for trial eligibility. Using OCTANE, we annotated 5,439 oncology clinical trials (4,438 genomically informed trials) that collectively were associated with 1,453 drugs, 779 genes, and 252 cancer types. The update module monitors trial change logs, identifies critical change events, and alerts the annotators when manual intervention may be needed. The annotation module establishes the database schema, implements data integration necessary for automation, and provides an annotation interface. The data aggregation module automates retrieval, aggregation, and update of trial information. To illustrate how the framework can be applied at an institution, we describe how we implemented an instance of OCTANE at a large cancer center. Furthermore, we present OCTANE (Oncology Clinical Trial Annotation Engine), an informatics framework supporting these processes in a scalable fashion. We describe processes for establishing and maintaining a clinical trial database, focusing on genomically informed trials. A comprehensive and up-to-date trial database is necessary for optimal patient-trial matching. Therefore, routine precision oncology using biomarker-based assignment to drug depends on matching patients to clinical trials. ![]() ![]() Many targeted therapies are currently available only via clinical trials. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |